Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Related MRK
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)
Related GE
Pacific Crest: Metal 3D Printing Offers High Growth, But Investing In The Technology Is Challenging
Fast Money Catch-Up Trades
Is Your Portfolio Ready for the IOT Boom? (Fox Business)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News

 

Related Articles (GE + MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters